Taysha Gene Therapies (NASDAQ:TSHA) Given New $8.00 Price Target at Citizens Jmp

Taysha Gene Therapies (NASDAQ:TSHA) had its target price increased by stock analysts at Citizens Jmp from $6.00 to $8.00 in a research note issued on Wednesday,Benzinga reports. The brokerage presently has a “market outperform” rating on the stock. Citizens Jmp’s price objective points to a potential upside of 87.35% from the company’s current price.

Several other research firms also recently commented on TSHA. Bank of America began coverage on Taysha Gene Therapies in a research report on Friday, July 11th. They issued a “buy” rating and a $8.00 target price on the stock. Robert W. Baird lifted their target price on Taysha Gene Therapies from $7.00 to $12.00 and gave the stock an “outperform” rating in a report on Thursday, October 2nd. Chardan Capital reissued a “buy” rating and issued a $12.00 target price on shares of Taysha Gene Therapies in a research report on Friday, October 17th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Taysha Gene Therapies in a research report on Thursday, October 30th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $10.00 price objective on shares of Taysha Gene Therapies in a report on Friday, October 17th. One research analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $9.50.

Taysha Gene Therapies Stock Performance

Taysha Gene Therapies stock opened at $4.27 on Wednesday. The company has a debt-to-equity ratio of 0.17, a current ratio of 12.48 and a quick ratio of 12.48. The firm has a market capitalization of $1.16 billion, a P/E ratio of -12.56 and a beta of 1.00. Taysha Gene Therapies has a 52-week low of $1.05 and a 52-week high of $5.51. The stock has a fifty day moving average price of $3.93 and a two-hundred day moving average price of $3.03.

Taysha Gene Therapies (NASDAQ:TSHA) last announced its quarterly earnings data on Tuesday, August 12th. The company reported ($0.09) EPS for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.02). The company had revenue of $1.99 million for the quarter, compared to analyst estimates of $1.61 million. Taysha Gene Therapies had a negative return on equity of 78.44% and a negative net margin of 1,144.97%. As a group, analysts anticipate that Taysha Gene Therapies will post -0.35 EPS for the current fiscal year.

Insider Activity

In related news, insider Sukumar Nagendran sold 200,000 shares of Taysha Gene Therapies stock in a transaction that occurred on Wednesday, September 10th. The shares were sold at an average price of $3.23, for a total value of $646,000.00. Following the transaction, the insider directly owned 1,006,439 shares of the company’s stock, valued at $3,250,797.97. This trade represents a 16.58% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Corporate insiders own 3.78% of the company’s stock.

Hedge Funds Weigh In On Taysha Gene Therapies

A number of institutional investors have recently modified their holdings of the business. ST Germain D J Co. Inc. lifted its position in shares of Taysha Gene Therapies by 81.8% during the 3rd quarter. ST Germain D J Co. Inc. now owns 9,633 shares of the company’s stock worth $32,000 after buying an additional 4,333 shares during the last quarter. Marex Group plc acquired a new position in Taysha Gene Therapies during the second quarter worth about $29,000. E Fund Management Co. Ltd. bought a new position in shares of Taysha Gene Therapies in the second quarter worth about $31,000. May Hill Capital LLC bought a new position in shares of Taysha Gene Therapies in the second quarter worth about $37,000. Finally, Principal Financial Group Inc. grew its holdings in shares of Taysha Gene Therapies by 33.6% during the 3rd quarter. Principal Financial Group Inc. now owns 16,251 shares of the company’s stock valued at $53,000 after purchasing an additional 4,091 shares during the last quarter. Institutional investors and hedge funds own 77.70% of the company’s stock.

Taysha Gene Therapies Company Profile

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.